GR44251 - GAlette (Geographic Atrophy Secondary to Age-Related Macular Degeneration) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called OpRegen (the study drug) is a safe and effective option for older adults who have geographic atrophy (GA) secondary to age-related macular degeneration (AMD). We also want to know if a procedure called subretinal surgical delivery is an effective way to give people the study drug.
Geography Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Who Can Participate in the Study?
Adults ages 50+ who:
- Are diagnosed with GA secondary to AMD
- Have never received stem cell treatments or gene therapy for their eyes
For more information, contact the study team at victoria.griffiths@duke.edu.
What is Involved?
If you choose to join this study, you will have the study drug delivered into the back of your eye through a surgical procedure. We will schedule you to come in for follow-up visits to check up on your eyes for up to 5 years after the procedure. There will be approximately 24 visits throughout the study.
During your study visits, you will have vision tests and eye exams.
Study Details
